1 Min Read
May 22 (Reuters) - XBiotech Inc:
* XBIOTECH ANNOUNCES FIRST PATIENT IN PHASE 2 STUDY EVALUATING MABP1 IN PATIENTS WITH ATOPIC DERMATITIS Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.